Finding New Molecular Targets of Two Copper(II)-Hydrazone Complexes on Triple-Negative Breast Cancer Cells Using

Lucia M Balsa1, María R Rodriguez1, Verónica Ferraresi-Curotto2

  • 1CEQUINOR (UNLP, CCT-CONICET La Plata, Asociado a CIC), Departamento de Química, Facultad de Ciencias Exactas, Universidad Nacional de La Plata, La Plata 1900, Argentina.

Insights

Copper compounds show promise against triple-negative breast cancer (TNBC). This study identified molecular mechanisms, including endoplasmic reticulum stress and mutant p53 downregulation, revealing potential new treatments for TNBC.

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Oncology

Background:

  • Triple-Negative Breast Cancer (TNBC) presents a significant clinical challenge due to limited treatment options and poor prognosis.
  • Copper compounds are emerging as potential anticancer agents, offering an alternative to conventional platinum-based chemotherapy.

Purpose of the Study:

  • To investigate the molecular mechanisms of two copper(II)-hydrazone complexes against TNBC cells.
  • To identify differentially expressed proteins and affected pathways using advanced proteomics and bioinformatics.

Main Methods:

  • Label-free quantitative proteomics was employed to analyze protein expression changes in MDA-MB-231 cells treated with copper complexes.
  • Functional bioinformatics strategies were used to elucidate the biological pathways impacted by the copper compounds.

Main Results:

  • Copper complexes induced endoplasmic reticulum stress and unfolded protein response.
  • Downregulation of proteins involved in DNA replication, repair, and lipid metabolism was observed.
  • Significant downregulation of gain-of-function-mutant p53 was identified as a key anticancer mechanism.

Conclusions:

  • Copper(II)-hydrazone complexes exhibit potent anticancer effects against TNBC by modulating key cellular pathways.
  • These compounds represent a promising therapeutic strategy, potentially offering improved efficacy and reduced side effects compared to current treatments.
  • The observed downregulation of lipid synthesis proteins suggests a novel therapeutic avenue for managing TNBC.

Related Concept Videos